Dataset Information

Increase in negative charge of ⁶⁸Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules.

ABSTRACT: Upregulation of the human epidermal growth factor receptor type 3 (HER3) is a common mechanism to bypass HER-targeted cancer therapy. Affibody-based molecular imaging has the potential for detecting and monitoring HER3 expression during treatment. In this study, we compared the imaging properties of newly generated ⁶⁸Ga-labeled anti-HER3 affibody molecules (HE)₃-Z_HER3-DOTA and (HE)₃-Z_HER3-DOTAGA with previously reported [⁶⁸Ga]Ga-(HE)₃-Z_HER3-NODAGA. We hypothesized that increasing the negative charge of the gallium-68/chelator complex would reduce hepatic uptake, which could lead to improved contrast of anti-HER3 affibody-based PET-imaging of HER3 expression. (HE)₃-Z_HER3-X (X = DOTA

SUBMITTER: Rinne SS

PROVIDER: S-EPMC6881397 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Increase in negative charge of ⁶⁸Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Increase in negative charge of 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Increase in negative charge of ⁶⁸Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules.